Lisuride and bromocryptine in L-Dopa stable-responder Parkinsonian patients: A comparative, double-blind evaluation of cardiopressor and neurochemical effects

Functional Neurology

Volumn 11, Issue 6, 1996, Pages 317-325

  Micieli, Giuseppe ^a,d   Martignoni, Emilia ^a   Cavallini, Anna ^a   Pacchetti, Claudio ^a   Rossi, Francesco ^b   Horowski, Rainard ^c   Nappi, Giuseppe ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b IRCCS NEUROMED   (Italy)

^c Shering AG   (Germany)

^d C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

bromocryptine; cardiopressor responses; catecholamines; lisuride; Parkinson's disease

Indexed keywords

BROMOCRIPTINE; LEVODOPA; LISURIDE; NORADRENALIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEMODYNAMICS; HUMAN; MALE; ORTHOSTATIC HYPOTENSION; PARKINSONISM; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTIPARKINSON AGENTS; BLOOD PRESSURE; BRAIN CHEMISTRY; BROMOCRIPTINE; DOUBLE-BLIND METHOD; FEMALE; FOOD-DRUG INTERACTIONS; HEART RATE; HEMODYNAMIC PROCESSES; HUMANS; LEVODOPA; LISURIDE; MALE; MIDDLE AGED; PARKINSON DISEASE; TILT-TABLE TEST;

EID: 0030432888     PISSN: 03935264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Yoshikawa T. Free radicals and their scavenger in Parkinson's disease. Eur Neurol 1993;33(suppl 1):60-68
2. Goldstein M, Lieberman AN, Takesugi N. The antiparkinsonian activity of dopamine agonists and their interaction with central dopamine receptor subtypes. Adv Neurol 1990;53:101-106
3. Goetz CG, Dierich NJ. Dopaminergic agonists in the treatment of Parkinson's disease. Neurol Clin 1992;10(Suppl 2):527-540
4. Przuntel H, Welzel D, Schawarzmann D, Letzel H, Kraus PH. Primary combination therapy of early Parkinson's disease. Eur Neurol 1992;32(suppl 1):36-45
5. Ruine UK. Combined BCT-levodopa therapy early in Parkinson's disease. Neurology 1985;35:1196-1198
6. Suchy I, Horowsky R. Effects of dopaminergic ergot derivatives on the vegetative system. In: Agnoli A, Bertolani G, eds Disordini autonomici e correlati neuroendocrini delle malattie extrapiramidali. Rome: Guanella D 1984;99-106
7. Micieli G, Martignoni E, Cavallini A, Sandrini G, Nappi G. Post-prandial and orthostatic hypotension in Parkinson's disease. Neurology 1987;37(Suppl 3):386-393
8. Cavallini A, Micieli G, Martignoni E, Blandini F, Fariello R, Nappi G. Cardiopressor effects of short-term treatment with cabergoline in L-dopa stable responder Parkinsonian patients: relevance of postprandial hypotension. Clin Neuropharmacology 1991;14(Suppl 4):343-351
9. Mercuri NB, Calabresi P, Bernardi G. Physiology and pharmacology of dopamine D2 receptors: their implications in dopamine-substitute therapy for Parkinson's disease. Neurology 1989;39:1106-1108
10. Clark D, White FG. DI dopamine receptor-the search for a functional critical evaluation of the D1/D2 dopamine receptor classification and its functional implications. Synapse 1987;1:347-388.
11. Ewing DF. Recent advances in the non-invasive investigation of diabetic autonomic neuropathy. In: Bannister R ed Autonomic failure. Oxford: Oxford University Press, 1988:667-689
12. Melzi D'Eril G. Catecholamines in human fluid using HPLC with electrochemical detection. Funct Neurol 1986; 1:182-190
13. Micieli G, Martignoni E, Bono G et al. A study of the cardiopressor effects of lisuride in the treatment of parkinsonism and pathological aging brain. Clin Neuropharmacol 1989;12(Suppl 5):404-415
14. Durrieu G, Senard JM, Tran MA, Rascol A, Montastruc JL. Effects of levodopa and bromocryptine on blood pressure and plasma catecholamines in Parkinsonians. Clin Neuropharmacol 1991;14(Suppl 1):84-90
15. Runge I, Horowski R. Can we differentiate symptomatic and neuroprotective effects in Parkinsonism? J Neural Transm 1991;4: 273-283